Melanotan II
What the Research Actually Shows
Human: 2 studies, 4 groups · Animal: 2 · In Vitro: 1
The underground tanning peptide that accidentally enhanced sexual desire—and why its unresolved melanoma risk and one 12-person trial make it the cautionary tale behind PT-141's FDA approval
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
2Clinical Trials
3Pilot / Limited Human Data
4Preclinical Only
~It’s Complicated
Reasonable Bet
Eyes Open
Thin Ice
Melanotan II is a synthetic peptide that activates melanocortin receptors throughout the body—darkening skin, suppressing appetite, and enhancing sexual arousal all at once. It was discovered in a University of Arizona tanning lab in the 1980s and has been used in underground bodybuilding and sexual enhancement communities for decades. The formal evidence is thin: one uncontrolled trial in 12 men showed spontaneous erections, but no controlled human trial has ever been conducted for sexual function or any other indication. The biggest concern is melanoma risk—Melanotan II activates the same pigmentation receptors that govern melanocyte growth, and no prospective study has ruled out increased cancer risk. A cleaner version—PT-141—was engineered from Melanotan II and is now FDA-approved. This is the parent compound, and its story matters.
Melanotan II is a cyclic heptapeptide that activates all five melanocortin receptor subtypes with roughly equal potency. That non-selectivity is both its appeal and its problem: it tans the skin, enhances sexual desire, and suppresses appetite in a single injection—but it cannot separate these effects, and the pigmentation pathway raises a melanoma question that decades of use have failed to answer.
Synthesized at the University of Arizona in the late 1980s as a research tool for melanocortin biology, Melanotan II was never developed as a pharmaceutical. It entered underground markets in the 1990s, where bodybuilders discovered its tanning and sexual effects. One small human trial—Wessells 1998, 12 men, uncontrolled—confirmed that melanocortin agonism could induce erections. That trial launched the development of PT-141 (bremelanotide), a truncated, cyclized derivative engineered for MC4R selectivity. PT-141 went on to earn FDA approval. Melanotan II stayed underground.
This article examines the evidence behind Melanotan II's effects, the unresolved safety concerns that kept it from regulatory approval, and why understanding this compound is essential to understanding its successor.
In This Article
Quick Facts: Melanotan II at a Glance
Type
Cyclic heptapeptide (non-selective melanocortin agonist)
Also Known As
MT-II, MT-2, Melanotan 2, barbie drug
Generic Name
Melanotan II (no INN assigned)
Brand Name
None — never commercially developed
Molecular Weight
~1,024 Da
Peptide Sequence
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH (cyclic heptapeptide with intramolecular lactam bridge)
Endogenous Origin
No direct endogenous equivalent; mimics α-melanocyte-stimulating hormone (α-MSH) signaling across all melanocortin receptor subtypes
Primary Molecular Function
Non-selective MC1R/MC3R/MC4R/MC5R agonist — activates melanocortin receptors in skin (tanning), hypothalamus (sexual arousal, appetite), and sebaceous glands (sebum production) simultaneously
Active Fragment
Contains the His-D-Phe-Arg-Trp pharmacophore shared with α-MSH and PT-141; non-selective activation means all melanocortin effects are bundled
Related Compound Relationship
Parent compound of PT-141 (bremelanotide); PT-141 was engineered from Melanotan II by truncation and cyclization to achieve >5,000-fold MC4R selectivity over MC1R, eliminating pigmentation while preserving sexual arousal
Clinical Programs
Phase 2 only (Wessells 1998, erectile dysfunction, N=12); Phase 1 safety/PK (Dorr, ~20 subjects); no active clinical development
Route
Subcutaneous injection (community: 0.25–1.0 mg); intranasal reported but efficacy uncharacterized
FDA Status
Not approved for any indication — research chemical only; marketing for human use prohibited under FDCA
WADA Status
Not explicitly listed on WADA Prohibited List; melanocortin agonists monitored; no evidence of performance enhancement
Half-Life
Estimated ~3–4 hours (limited PK data; never formally characterized in rigorous studies)
Key Safety Signal
Unresolved melanoma risk from MC1R-mediated melanogenesis; nausea in 60–80% of users; mole darkening complicates melanoma surveillance; unregulated supply chain
Evidence Tier
3 Pilot / Limited Human Data
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
What Is Melanotan II?
Pronunciation: mel-AN-oh-tan too
Your skin has a defense system against ultraviolet radiation, and it runs on melanocortin signaling. When UV light hits your skin, your body produces alpha-melanocyte-stimulating hormone (α-MSH), which activates MC1R receptors on melanocytes, triggering melanin production—the pigment that darkens skin and absorbs UV energy. Melanotan II is a synthetic peptide that hijacks this pathway, but it does not stop at the skin. It activates melanocortin receptors everywhere—in the brain's arousal circuits, in the hypothalamic appetite centers, in sebaceous glands. Everything at once.
Melanotan II is a cyclic heptapeptide synthesized at the University of Arizona in the late 1980s by Robert Dorr and colleagues as a research tool for studying melanocortin biology. Unlike its successor PT-141, which was engineered for selectivity, Melanotan II activates all five melanocortin receptor subtypes (MC1R through MC5R) with roughly equal potency (Ki values of 1–10 nM across subtypes). This means a single injection produces skin darkening (MC1R), sexual arousal (MC3R/MC4R), appetite suppression (MC4R/MC5R), increased sebum production (MC5R), and nausea—all bundled together.
The compound was never developed as a pharmaceutical. It entered underground bodybuilding markets in the 1990s, where its combined tanning and sexual effects attracted a devoted user base. It remains available from grey-market suppliers and underground labs, though product quality is highly variable.
PLAIN ENGLISH
Melanotan II is a lab-made peptide that was designed to study tanning biology. It darkens skin, boosts sexual desire, and kills appetite—all from one injection—because it activates a family of receptors throughout the body without discrimination. It was never approved as a drug, and its most concerning side effect—potential melanoma risk—has never been resolved.
Origins and Discovery
The melanocortin story begins in the 1950s, when biochemists first characterized α-MSH as the hormone responsible for skin pigmentation in amphibians and mammals. By the 1980s, researchers at the University of Arizona were synthesizing analogs of α-MSH to study melanocortin receptor biology—and to explore the possibility of a sunless tanning agent that could protect fair-skinned populations from UV-induced skin cancer.
Robert Dorr and colleagues synthesized Melanotan II as a potent, stable analog of α-MSH. The compound worked: injected into volunteers, it reliably darkened skin within days. What the researchers did not anticipate—and what changed the trajectory of melanocortin pharmacology—was the sexual side effects. Male volunteers reported spontaneous erections and heightened arousal. The effect was not subtle, and it was not rare.
This accidental discovery split the melanocortin field in two directions. The tanning application stalled—regulatory agencies were uneasy about a drug that activated melanocytes, the very cells that become cancerous in melanoma. The sexual application gained traction. Palatin Technologies licensed the intellectual property and began engineering a more selective derivative—truncating and cyclizing the peptide to create PT-141, which preserved the MC4R sexual arousal signaling while reducing MC1R pigmentation activity by more than 5,000-fold.
Melanotan II itself was abandoned by the academic research community by the early 2000s. But it had already escaped into underground markets. Bodybuilders, tanning enthusiasts, and sexual wellness communities adopted it as an inexpensive, potent, multi-effect peptide—and it has remained in grey-market circulation ever since.
PLAIN ENGLISH
Melanotan II was invented as a tanning drug in the 1980s. When test subjects started getting spontaneous erections, the researchers realized they had stumbled onto something bigger. The tanning drug was never approved—melanoma concerns killed the application—but the sexual side effect led to PT-141, which eventually became an FDA-approved drug. Melanotan II itself stayed underground.
Mechanism of Action
Non-Selective Melanocortin Agonism
Melanotan II binds to and activates all five melanocortin receptor subtypes with high affinity. This non-selectivity is the defining pharmacological characteristic—and the root of both its appeal and its problems.
MC1R: Pigmentation
MC1R activation on melanocytes triggers the Gαs/cAMP/CREB pathway, upregulating tyrosinase and increasing eumelanin synthesis. The result is visible skin darkening within 3–7 days of initial dosing. This is the same pathway that natural UV exposure activates, but Melanotan II bypasses the UV requirement—it darkens skin without sun exposure. The concern: MC1R-driven melanocyte proliferation and melanin production are the same processes dysregulated in melanoma.
MC3R/MC4R: Sexual Arousal
Hypothalamic MC3R and MC4R activation produces the same central sexual arousal signaling as PT-141—dopaminergic and oxytocinergic pathway enhancement in the paraventricular nucleus. Melanotan II's sexual effect is anecdotally described as more potent than PT-141's, possibly because simultaneous MC3R and MC4R co-activation produces a stronger downstream signal than MC4R activation alone.
MC4R/MC5R: Appetite and Metabolism
MC4R activation in the lateral hypothalamus suppresses appetite—the same mechanism that endogenous α-MSH uses to regulate satiety. Users commonly report reduced food intake and modest weight loss during Melanotan II courses. MC5R activation in sebaceous glands increases sebum production, causing oily skin and acne exacerbation.
Why Selectivity Matters
Every desired effect of Melanotan II comes bundled with effects the user may not want. Sexual arousal arrives with skin darkening and nausea. Appetite suppression arrives with oily skin. There is no pharmacological way to separate these effects because the compound activates all melanocortin subtypes indiscriminately. PT-141 solved this by engineering MC4R selectivity—eliminating pigmentation while preserving sexual arousal. This is why PT-141 succeeded as a drug and Melanotan II did not.
PLAIN ENGLISH
Melanotan II turns on every melanocortin receptor in the body at the same time. That means you get tanning, sexual arousal, and appetite suppression in one shot—but you also get nausea, oily skin, and a melanoma question mark. PT-141 was built specifically to keep the sexual effect and get rid of everything else.
Key Research Areas and Studies
The Wessells Trial (1998)
The only published human trial specifically examining Melanotan II's sexual effects enrolled 12 men—8 healthy and 4 with erectile dysfunction—in an open-label, non-randomized design. Subcutaneous Melanotan II at doses of 0.1–0.25 mg induced spontaneous erections in 11 of 12 participants within 8–16 hours. Erection quality improved in the men with ED.
This trial established proof-of-concept: melanocortin agonism can enhance sexual function in humans. It is also, critically, the only formal evidence for this claim. The trial had no placebo control, no standardized assessment tool, no blinding, and a sample size of 12. PMID 9892497
The Dorr Melanogenesis Studies (1989–1995)
Robert Dorr's University of Arizona group conducted the foundational work on Melanotan II's receptor binding, melanogenesis, and basic pharmacokinetics. These studies established the compound's receptor affinity profile (non-selective, Ki 1–10 nM across MC1R–MC5R) and confirmed dose-dependent skin darkening in human volunteers. Phase 1 safety data from approximately 20 subjects documented nausea, flushing, and spontaneous erections as expected pharmacological effects. PMID 2572056
The Melanocortin Sexual Behavior Literature
Pfaus and colleagues at McGill University published the seminal review establishing the MC4R circuit as critical for sexual motivation in rodents and primates. MC4R knockout mice show reduced sexual behavior; melanocortin agonists—including Melanotan II—rescue this deficit. This animal literature provides the mechanistic foundation for both Melanotan II and PT-141. PMID 15520816
The Melanoma Question
No prospective study has been designed to assess melanoma risk in Melanotan II users. The theoretical concern is straightforward: MC1R activation increases melanocyte proliferation and melanin production—the same processes that are dysregulated in melanoma. Moles darken and become more prominent during Melanotan II use, complicating melanoma surveillance. Population-level melanoma surveillance data (2000–2025) do not show a correlation with Melanotan II community use, but the user population is small and self-selected, making epidemiological detection difficult.
PLAIN ENGLISH
The main evidence for Melanotan II's sexual effects is a single trial in 12 men with no placebo group. The tanning effect is well-documented. The melanoma risk has never been formally studied—it remains a theoretical concern that no one has proven or disproven.
The Melanotan II–PT-141 Relationship
Understanding Melanotan II requires understanding its relationship to PT-141, the FDA-approved drug it spawned.
From Parent to Product
Palatin Technologies took Melanotan II's structure and asked: can we keep the MC4R sexual arousal signaling and eliminate the MC1R pigmentation? The answer was PT-141—a truncated, cyclized heptapeptide with >5,000-fold selectivity for MC4R over MC1R. The engineering succeeded on every metric: PT-141 does not darken skin, does not proliferate melanocytes, and does not raise melanoma concerns. It retained the sexual arousal effect and went through Phase 3 trials to FDA approval.
Why Users Still Choose Melanotan II
Despite PT-141's superiority on paper, Melanotan II remains popular for three reasons. First, cost: Melanotan II is approximately $5–10 per dose from grey-market suppliers versus $900–1,500 per dose for PT-141 (Vyleesi). Second, the bundled effects—some users want tanning, appetite suppression, and sexual arousal simultaneously. Third, anecdotal reports suggest Melanotan II's sexual effect may be more potent than PT-141's, possibly due to MC3R/MC4R co-activation. None of these reports are controlled.
The Selectivity Lesson
Melanotan II's story illustrates a core principle in pharmacology: non-selective drugs produce non-selective effects. The melanocortin receptors govern pigmentation, sexual arousal, appetite, sebum production, and adrenal function. Activating all of them at once is pharmacologically crude. PT-141 represents the precision alternative—and the clinical success that precision enabled.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Melanotan II enhances sexual function in men"” | Wessells 1998 (N=12, open-label, no placebo) showed spontaneous erections in 11/12 men. Community reports are extensive but uncontrolled. | Preclinical Only |
| “"Melanotan II provides a safe, UV-free tan"” | MC1R activation reliably darkens skin, confirmed in multiple studies. However, "safe" is unproven—melanoma risk from MC1R-driven melanocyte proliferation has never been formally assessed. | Mixed Evidence |
| “"Melanotan II suppresses appetite and aids weight loss"” | MC4R/MC5R-mediated appetite suppression is established in animal models and confirmed by user reports. No controlled human trial has quantified the effect. | Preclinical Only |
| “"Melanotan II is safer than people think"” | No long-term safety data exist. No prospective melanoma study. No quality control on grey-market products. The safety profile is uncharacterized, not established. | Unsupported |
| “"Melanotan II works better than PT-141 for sexual arousal"” | Anecdotal comparisons only. No head-to-head trial exists. MC3R/MC4R co-activation may produce a stronger signal, but this is mechanistic speculation. | Preclinical Only |
| “"Melanotan II causes melanoma"” | No causal evidence in humans. MC1R activation increases melanogenesis and theoretically could increase melanoma risk, but population data show no correlation. The concern is legitimate but unproven. | Mixed Evidence |
| “"Melanotan II works for women too"” | No human trial in women for sexual function. Mechanism (MC4R) is sex-independent. Animal data support efficacy in female rodents. Extrapolation to human women is unsupported by clinical evidence. | Preclinical Only |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
Wessells et al., 1998 (Erectile Function)
Design: Open-label, non-randomized. N=12 (8 healthy men, 4 with ED). Subcutaneous Melanotan II at 0.1–0.25 mg dose escalation.
Findings: Spontaneous erections in 11/12 men within 8–16 hours. Improved erection quality in ED patients. Dose-dependent nausea and facial flushing.
Limitations: No placebo control. No blinding. Subjective erection assessment only (no validated instrument). N=12. Cannot distinguish pharmacological effect from expectation bias. Open-label design inflates observed effect size.
Dorr et al., ~1992 (Phase 1 Safety/PK)
Design: Open-label Phase 1 in approximately 20 healthy volunteers. Dose escalation with PK sampling.
Findings: Dose-dependent skin darkening within 3–7 days. Nausea in majority of subjects. Facial flushing. Spontaneous erections reported. Estimated half-life ~3–4 hours. No serious adverse events.
Limitations: Results not systematically published in peer-reviewed journal. Limited PK characterization. No long-term follow-up.
PMID: Not available (limited publication)
The Evidence Gap
No controlled trial of Melanotan II for any indication has been published. No dose-ranging study for sexual function exists. No trial in women exists. No long-term safety study exists. The compound's development was abandoned in the early 2000s when PT-141 proved superior. The evidence base consists of one 12-person uncontrolled trial, Phase 1 safety data in ~20 subjects, and decades of uncontrolled community reports.
Safety, Risks, and Limitations
Nausea
Nausea is reported by 60–80% of Melanotan II users—substantially higher than the 43% rate seen with PT-141. The nausea is dose-dependent, typically onset within 30 minutes to 2 hours, and resolves within 4–6 hours. It is the primary limiting factor for adherence.
The Melanoma Question
This is the safety issue that defines Melanotan II. MC1R activation in melanocytes increases eumelanin production and, theoretically, could promote melanocyte proliferation—the cellular process underlying melanoma. Moles darken and become more prominent during use, complicating visual melanoma screening. No prospective study has assessed melanoma incidence in Melanotan II users. Population-level surveillance data do not show a spike, but the user population is small and self-selected, making epidemiological detection difficult.
Dermatologists generally discourage Melanotan II use in patients with personal or family history of melanoma, dysplastic nevi, or fair skin (Fitzpatrick types I–II)—the very populations most likely to seek sunless tanning.
Cardiovascular Effects
Transient systolic blood pressure increases of 5–15 mmHg are reported. This is more pronounced than PT-141's 3–8 mmHg increase, likely due to non-selective receptor activation. No cardiovascular events have been formally attributed to Melanotan II, but the user population is young and healthy, potentially masking risk.
Supply Chain Risk
Melanotan II is an unregulated research chemical. Products from grey-market suppliers frequently contain impurities—synthesis byproducts, bacterial endotoxins, heavy metals, and mislabeled compounds. This supply chain risk is a practical safety hazard distinct from the compound's pharmacological risks. Users injecting contaminated material face risks of infection, allergic reaction, and exposure to unknown substances.
Other Adverse Effects
Facial flushing (40–50%), spontaneous erections in men (30–50%, can persist for hours), headache (20–30%), increased sebum production and acne exacerbation (10–30%), and appetite suppression (40–60%) are commonly reported. Ocular pigmentation (iris darkening) has been reported anecdotally; clinical significance unknown.
What Is Not Known
Long-term effects of chronic melanocortin stimulation on the immune system, neuroendocrine axis, and reproductive function are unstudied. No fertility data exist. No hepatic or renal safety data exist beyond the limited Phase 1 characterization. The safety profile in women is entirely uncharacterized.
PLAIN ENGLISH
The biggest unknown with Melanotan II is melanoma risk—nobody has done the study to prove or disprove it. The nausea is worse than PT-141. The supply chain is unregulated, so you may not be getting what you think you are getting. And we have essentially zero long-term safety data.
Legal and Regulatory Status
No Regulatory Approval
Melanotan II is not approved by the FDA, EMA, TGA, or any regulatory agency for any indication. It was never submitted for regulatory review. The investigational new drug (IND) process was not pursued in the modern regulatory era.
US Legal Status
Melanotan II is not a DEA-scheduled substance. Possession for personal use occupies a legal grey zone—it is not explicitly illegal to possess, but marketing, distributing, or selling it for human use violates the Federal Food, Drug, and Cosmetic Act. The FDA has issued warning letters to companies marketing Melanotan II as a consumer product.
International Status
Legal status varies by country. In Australia, the TGA has explicitly warned against Melanotan II use and classifies it as an unapproved therapeutic good. In the United Kingdom, it is not a controlled substance but cannot be legally sold for human consumption. In several European countries, grey-market sales continue despite regulatory warnings.
WADA Status
Not on the WADA Prohibited Substances List. Melanocortin agonists are monitored, but no evidence supports performance-enhancing effects. Athletes should verify current WADA status before use.
CRITICAL DISCLAIMER
Melanotan II is an unregulated research chemical. Products purchased from grey-market or underground sources have no quality assurance. Users face risks of contamination, mislabeling, and unknown impurities in addition to the compound's inherent pharmacological risks.
Research Protocols and Formulation Considerations
Typical Research Material
Melanotan II is available from research chemical suppliers as a lyophilized powder (typically 10 mg vials). Reconstitution requires bacteriostatic water. The compound is light-sensitive and should be stored refrigerated (2–8°C) after reconstitution. Shelf life after reconstitution is estimated at 4–6 weeks refrigerated.
Pharmacokinetic Profile
Limited formal PK data. Estimated half-life of 3–4 hours from early Phase 1 work. Cmax and Tmax not rigorously characterized. Metabolism presumed primarily hepatic. Excretion pathways not formally studied.
Quality Concerns
Research-grade Melanotan II from legitimate suppliers typically comes with certificates of analysis (CoA) showing purity >98% by HPLC. Grey-market products frequently fail independent testing—purity ranges from 50–95% in published analyses, with impurities including synthesis byproducts, degradation products, and bacterial contamination.
Dosing in Published Research
WHY NO DOSING CHART?
No published dose-response study exists for Melanotan II. The doses reported in the research literature were used in specific experimental contexts, not established through systematic dose-optimization trials. Without controlled data comparing different doses, routes, or durations, we cannot responsibly present a clinical dosing table. What the published studies used is described in the text below.
Published Dosing Data
The Wessells 1998 trial used dose escalation from 0.1 to 0.25 mg subcutaneous in men. Dorr's Phase 1 studies used similar dose ranges. No dose-response curve for sexual function has been formally established. No maximum tolerated dose has been defined.
Pharmacological Context
Melanotan II's receptor affinities (Ki 1–10 nM across subtypes) are similar to PT-141's MC4R affinity, but because it activates all receptors, lower doses may produce clinically relevant effects across multiple endpoints simultaneously. The absence of formal dose-ranging data means that optimal dosing for any specific effect (tanning vs. sexual arousal vs. appetite suppression) cannot be separated pharmacologically.
Dosing in Self-Experimentation Communities
WHY NO DOSING CHART?
No published dose-response study exists for Melanotan II. The doses reported in the research literature were used in specific experimental contexts, not established through systematic dose-optimization trials. Without controlled data comparing different doses, routes, or durations, we cannot responsibly present a clinical dosing table. What the published studies used is described in the text below.
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
[Critical Disclaimer — Community Dosing] The following section describes dosing protocols reported in self-experimentation communities. These protocols are not derived from controlled clinical trials and have no published safety validation. Peptidings documents them because they exist in practice and because practitioners and patients may encounter them. Documentation is not endorsement.
Community Loading Protocol
Community protocols typically describe a "loading phase" of 0.25–0.5 mg subcutaneous daily for 7–14 days, followed by a "maintenance phase" of 0.5–1.0 mg once or twice weekly. The loading phase is intended to saturate melanocortin receptors and initiate visible tanning; the maintenance phase sustains effects.
Community Dosing for Sexual Effects
Users seeking primarily sexual effects report doses of 0.5–1.0 mg subcutaneous approximately 2–4 hours before anticipated sexual activity. Some users describe tolerance development with repeated use, necessitating dose escalation. Others report consistent effects without escalation.
Anti-Nausea Strategies
Community protocols frequently include anti-emetic pre-treatment—diphenhydramine (Benadryl) or ondansetron (Zofran)—taken 30–60 minutes before injection. Some users report that nausea diminishes after the first 3–5 doses. Others find it persistent and dose-limiting.
What These Protocols Lack
No controlled trial has validated any community dosing protocol. No dose-response relationship has been established for any endpoint. No safety boundary has been defined. Users are experimenting on themselves without the safety infrastructure that clinical trials provide.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Melanotan II combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Melanotan II with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Frequently Asked Questions
What is Melanotan II?
Melanotan II is a synthetic cyclic heptapeptide that activates melanocortin receptors throughout the body. It was developed at the University of Arizona in the 1980s as a research tool for melanocortin biology. It darkens skin, enhances sexual desire, and suppresses appetite—all from a single injection. It has never been approved as a drug by any regulatory agency.
Is Melanotan II the same as PT-141?
No. PT-141 (bremelanotide, Vyleesi) was derived from Melanotan II through deliberate molecular engineering. PT-141 is more than 5,000 times more selective for the brain receptor responsible for sexual arousal (MC4R) compared to the skin-darkening receptor (MC1R). This means PT-141 enhances sexual desire without causing skin darkening. They share a pharmacological heritage but are different molecules with very different safety profiles.
Does Melanotan II cause melanoma?
This is the central unresolved safety question. Melanotan II activates MC1R on melanocytes, increasing melanin production—the same cellular machinery that is dysregulated in melanoma. No causal link has been proven in humans, but no prospective study has assessed the risk either. The concern is legitimate, not speculative.
How does Melanotan II work for sexual arousal?
It activates MC3R and MC4R receptors in the hypothalamus—the same mechanism as PT-141. These receptors are part of the brain circuitry that generates sexual desire. Unlike Viagra, which increases blood flow, Melanotan II works upstream in the brain to produce the wanting itself.
Is Melanotan II legal?
In the United States, Melanotan II is not a controlled substance, but it is not FDA-approved for human use. Marketing or selling it for human consumption is illegal. Possession for personal use exists in a legal grey zone. Legal status varies internationally—several countries have issued explicit warnings against its use.
What are the side effects?
Nausea (60–80% of users), facial flushing (40–50%), spontaneous erections in men (30–50%), headache (20–30%), increased sebum production and acne (10–30%), and appetite suppression (40–60%). The most concerning potential risk—melanoma—remains unquantified.
Why wasn't Melanotan II developed into a drug?
The melanoma risk from MC1R activation was the primary regulatory obstacle for the tanning indication. For the sexual function indication, Palatin Technologies chose to engineer a more selective derivative (PT-141) rather than develop the non-selective parent compound. PT-141 succeeded; Melanotan II was abandoned.
Is the Melanotan II sold online safe?
Quality varies enormously. Melanotan II from grey-market suppliers frequently fails independent testing—impurities include synthesis byproducts, bacterial endotoxins, heavy metals, and degradation products. Users face supply chain risks beyond the compound's own pharmacological risks.
Does Melanotan II work for women?
No controlled trial has tested Melanotan II in women for any indication. The mechanism (MC4R activation in the hypothalamus) is sex-independent, and animal data show melanocortin agonists enhance sexual behavior in female rodents. Extrapolation to human women is plausible but unproven.
How does Melanotan II compare to PT-141 for sexual effects?
Some community users report Melanotan II's sexual effect is more potent than PT-141's—possibly because MC3R/MC4R co-activation produces a stronger signal. No head-to-head trial exists. PT-141 has a 3,000-person safety database and FDA approval; Melanotan II has one 12-person uncontrolled trial and decades of anecdotal reports.
Can Melanotan II be used with other medications?
No formal drug interaction studies have been conducted. Metabolism is presumed hepatic, but pathways have not been characterized. Users should exercise extreme caution when combining Melanotan II with any medication, particularly cardiovascular drugs (due to blood pressure effects) or drugs metabolized by CYP enzymes.
What evidence tier does Peptidings assign to Melanotan II?
Peptidings rates Melanotan II as Tier 3: Pilot / Limited Human Data. This reflects one small uncontrolled human trial (N=12), limited Phase 1 safety data (~20 subjects), well-characterized in vitro receptor pharmacology, supportive animal data, and no active clinical development program. The mechanism is sound; the clinical evidence is minimal.
Related Compounds: How Melanotan II Compares
Melanotan II is one of seven compounds in the Peptidings Sexual Health & Hormonal cluster. The table below compares all compounds in this family across evidence tier, mechanism, FDA status, WADA status, and key limitations—so you can see exactly where each stands relative to the others.
| Compound | Type | Evidence Tier | Verdict | Mechanism | Primary Use Case | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| PT-141 (Bremelanotide) | Cyclic heptapeptide; MC3R/MC4R agonist; ~1,025 Da | Tier 1 — Approved Drug | Strong Foundation | MC4R agonism in hypothalamus → central sexual arousal pathway; 5,000-fold MC4R:MC1R selectivity (no pigmentation) | HSDD in premenopausal women (FDA-approved); off-label male sexual dysfunction | ~3,000 across Phase 1–3 (RECONNECT N=1,247; BLOOM N=1,247) | FDA-approved 2019 (Vyleesi, Palatin/Amag) | Prohibited (S2, males only) | 43% nausea rate; no postmenopausal efficacy (AFTERGLOW failed); SC injection only; limited long-term data |
| Melanotan II | Cyclic heptapeptide; non-selective melanocortin agonist; ~1,024 Da | Tier 3 — Pilot / Limited Human Data | Eyes Open | Non-selective MC1R/MC3R/MC4R/MC5R agonism → tanning (MC1R) + sexual arousal (MC4R) + appetite suppression (MC4R) | Tanning; sexual arousal; appetite suppression (all off-label/underground) | 1 small Phase 2 (Wessells, N=12, erectile response); ~20 Phase 1 PK | Not approved; development abandoned ~2000 | Prohibited (S2) | Non-selective → uncontrolled pigmentation, nevi darkening, unresolved melanoma risk; zero Phase 3 data; grey-market quality variable |
| Leuprolide | Nonapeptide; GnRH superagonist; 1,209 Da | Tier 1 — Approved Drug | Strong Foundation | GnRH-R super-agonism → initial flare (LH/T surge) → receptor desensitization → chemical castration; Kd ~0.1 nM | Prostate cancer; endometriosis; uterine fibroids; central precocious puberty | 500,000+ in registries; dozens of Phase 3 RCTs; decades of pharmacovigilance | FDA-approved 1985 (Lupron, Eligard, multiple generics) | Prohibited (S2) | Hot flashes 60–70%; bone density loss 2–3%/year; mood changes; temporary symptom flare at initiation |
| HCG (Human Chorionic Gonadotropin) | Glycoprotein hormone (~36,700 Da); LH/CG receptor agonist | Tier 1 — Approved Drug | Strong Foundation | LHCGR agonism → Leydig cell testosterone production; oocyte maturation trigger; 6–10× more potent than LH | Ovulation induction (IVF); male hypogonadism; fertility preservation during TRT; cryptorchidism | 500,000+ across decades; Cochrane reviews for IVF; multiple RCTs | FDA-approved 1967 (Pregnyl, Novarel, Ovidrel) | Prohibited (S2, males only) | OHSS risk 1–5% in IVF; removed from 503A compounding (2020 BPCIA); debunked for weight loss |
| HMG (Human Menopausal Gonadotropin) | Glycoprotein mixture (FSH + LH/HCG activity); urinary-derived | Tier 1 — Approved Drug | Strong Foundation | Dual FSH (follicular growth) + LH activity (theca steroidogenesis); two-cell two-gonadotropin model | Controlled ovarian stimulation (IVF); spermatogenesis induction in HH | 4,500+ across meta-analyses and RCTs; equivalent to rFSH for pregnancy rates | FDA-approved (Menopur, Ferring) | Prohibited (S2) | OHSS risk comparable to rFSH; urinary-derived (batch variability); requires specialist supervision |
| Kisspeptin-10 | Decapeptide; GPR54 (KISS1R) agonist; ~1,302 Da | Tier 2 — Clinical Trials | Reasonable Bet | GPR54 agonism on hypothalamic GnRH neurons → endogenous GnRH/LH release; master upstream regulator of HPG axis | IVF oocyte maturation trigger (OHSS-free); hypothalamic amenorrhea; HPG axis reactivation | ~145 across Phase 1–2 (IVF RCT N=60; HA studies; healthy volunteers) | Not approved (investigational; Phase 2 completed) | Not explicitly listed | ~4-minute half-life (KP-10); Phase 3 pending; KP-54 preferred for clinical use; no chronic dosing data |
| Oxytocin | Cyclic nonapeptide; OXTR agonist; 1,007 Da | Tier 1 — Approved Drug | Strong Foundation | OXTR (Gq/Gi-coupled) → uterine contraction (peripheral) + social cognition/bonding/stress modulation (central) | Labor induction/augmentation; postpartum hemorrhage; milk letdown; investigational: autism, anxiety, PTSD | 500,000+ obstetric use; autism RCT N=250 (negative); psychiatric meta-analyses | FDA-approved (Pitocin; Syntocinon outside US) | Not prohibited | Uterine hyperstimulation (dose-dependent); autism RCT negative; neuropsych results inconsistent; short half-life (3–5 min IV) |
Summary of Key Findings
Melanotan II is a pharmacologically active compound with a genuinely novel mechanism—non-selective melanocortin agonism that produces skin darkening, sexual arousal enhancement, and appetite suppression from a single injection. The mechanism is well-characterized at the receptor level, supported by animal data, and confirmed in one small human trial. The compound matters because it launched the development of PT-141, proving that melanocortin agonism could enhance sexual function in humans.
The evidence base, however, is sparse by any clinical standard. One uncontrolled trial in 12 men and Phase 1 data in approximately 20 subjects constitute the entirety of the published human evidence for sexual function. No controlled trial has been conducted for any indication. No dose-ranging data exist. No trial in women exists.
The safety profile is incompletely characterized and includes a significant unresolved concern: melanoma risk from MC1R-mediated melanocyte proliferation. Twenty-five years of community use have not produced a detectable melanoma signal, but the absence of evidence is not evidence of absence—the user population is small, young, and not systematically monitored.
Melanotan II occupies a specific niche: it is the parent compound of an FDA-approved drug, still in underground use because it is cheap and multi-functional, with a mechanism that is validated but a clinical evidence base that is not. Practitioners and patients should understand this compound because many people use it—and because understanding its limitations is essential to understanding why PT-141 was developed.
Verdict Recapitulation
Melanotan II earns Tier 3 and an Eyes Open verdict because the mechanism is well-characterized but the human evidence is minimal—one small, uncontrolled trial. The melanoma risk is unresolved. The supply chain is unregulated. A superior, FDA-approved alternative (PT-141) exists. The compound is pharmacologically interesting and historically important but not supported by the evidence base required for a more favorable rating.
For readers considering Melanotan II, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Melanotan II
Further Reading and Resources
If you want to go deeper on Melanotan II, the evidence landscape for sexual health & hormonal peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Sexual Health & Hormonal Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Melanotan II — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology, 1998;160(2):389–393. PMID 9892497
- Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot Phase I clinical study. Life Sciences, 1996;58(20):1777–1784. PMID 2572056
- Pfaus JG, Shadiack A, Van Soest T, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences, 2004;101(27):10201–10204. PMID 15520816
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 2006;27(4):921–930. PMID 16412534
- Evans-Brown M, McVeigh J, Perkins C, et al. Human enhancement drugs: the emerging challenges to public health. North West Public Health Observatory, 2012. ISBN: 978-1-908929-08-7
DISCLAIMER
Melanotan II is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 08, 2026. Next scheduled review: October 05, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.